NeOnc Technologies HoldingsNTHI -0.90%7 Current Ratio is 0.13 as of Mar. 2026, which is 7% below its 10-year median of 0.14. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 96.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NeOnc Technologies Holdings's current ratio for the quarter that ended in Mar. 2026 was 0.13.
NeOnc Technologies Holdings has a current ratio of 0.13. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If NeOnc Technologies Holdings has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for NeOnc Technologies Holdings's Current Ratio or its related term are showing as below:
NTHI'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.14 Max: 0.41
Current: 0.13
During the past 5 years, NeOnc Technologies Holdings's highest Current Ratio was 0.41. The lowest was 0.01. And the median was 0.14.
NTHI's Current Ratio is ranked worse than 96.53% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs NTHI: 0.13
NeOnc Technologies Holdings (NAS:NTHI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
NeOnc Technologies Holdings Current Ratio Related Terms
NeOnc Technologies Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTHI vs GUTS, PEPG, ENGN: Current Ratio Comparison
For the Biotechnology subindustry, NeOnc Technologies Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeOnc Technologies Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where NeOnc Technologies Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeOnc Technologies Holdings (NTHI) has a Current Ratio of 0.13 as of Mar. 2026. This is near median its historical median of 0.14. Over the past decade, NeOnc Technologies Holdings' Current Ratio has ranged from 0.01 to 0.41. According to the industry distribution chart, NeOnc Technologies Holdings ranks #1362 out of 1411 companies in the Biotechnology industry, placing it in the top 96.5%.
Is NeOnc Technologies Holdings' Current Ratio too high?
NeOnc Technologies Holdings' current Current Ratio of 0.13 is near median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.41. The Biotechnology industry median Current Ratio is 3.91. NeOnc Technologies Holdings' value of 0.13 is 96.7% below this industry median. Based on the distribution chart, NeOnc Technologies Holdings ranks #1362 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' Current Ratio compare to GUTS and PEPG?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #1362 out of 1411 companies for Current Ratio. This places NeOnc Technologies Holdings in the lower half of its industry. The industry median Current Ratio is 3.91. NeOnc Technologies Holdings' value of 0.13 is 96.7% below this benchmark. Historically, NeOnc Technologies Holdings' own Current Ratio has ranged from 0.01 to 0.41 over the past decade. While the company's 10-year median is 0.14 vs. the industry median of 3.91, NeOnc Technologies Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeOnc Technologies Holdings's current Current Ratio of 0.13 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeOnc Technologies Holdings's current Current Ratio is 0.13, which is near median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current Current Ratio of 0.13. The current Current Ratio is 0.13, which is near median its 10-year median of 0.14 and 96.7% below the Biotechnology industry median of 3.91. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current Current Ratio is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score
Get the complete analysis for NTHI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTHI has been successfully added to your 
